Brenda has been CHX’s VP of Administration for many years. Brenda is responsible for regulatory filings and renewals, the supply chain for Prevora, and for overseeing the monitoring and implementation of Phase III clinical studies.
CA, VP Finance
Gerry has been instrumental in contributing to our corporate strategy in chronic disease management.
Ross has served as CHX’s CEO and a director for 15 years. He is responsible for Prevora’s first-in-class regulatory approvals in Europe and Canada, for conducting years of observation of Prevora’s use in improving oral health, and most recently in establishing strategic marketing partnerships in Special Needs, Complex Needs and Geriatric Care.